Approval · Notice of Compliance 27409 · 2022
TEVA-NAPROXEN: Notice of Compliance 27409
Issued January 17, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27409
- Date
- January 17, 2022
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to labels to align with plain language labelling regulations
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-NAPROXEN | Not yet assigned | — |
| TEVA-NAPROXEN EC | Not yet assigned | — |